Eda Ataseven

Eda Ataseven

Auto-generated profile, based on publicly available information

Eda Ataseven

Department of Pediatric Oncology, Faculty of Medicine, Ege University, Izmir, Turkey

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2021 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
PDF file
EAEda Ataseven
Eda Ataseven
ŞGŞebnem Önen Göktepe
Şebnem Önen Göktepe
MKMehmet Kantar
Mehmet Kantar
Introduction: Ifosfamide is an alkylating agent, mostly used against variety of solid tumors in pediatric oncology practice. Although hemorrhagic cystitis is known as a common adverse effect, encephalopathy is the another one that should be kept in mind. It may occur in 2–5% of the children, and manifested by different clinical spectrums such as somnolence, lethargy, irritability, excitement, disorientation, confusion, weakness, hallucinations, seizures, movement disorders, and coma. Case report: Herein, we present two patients who developed generalized seizure activity and one who developed coma during ifosfamide infusion. Management and outcome: In the first two patients, ifosfamide infusion was discontinued and intravenous diazepam was given. Their seizure stopped in a few minutes and neurological examination was back to normal, and no focal deficits were observed. In the third patient, ifosfamide infusion was discontinued, methylene blue and thiamine were given. After the tenth dose of methylene blue, she became neurologically normal, without any mental and motor deficit. Nevertheless, later she developed febrile neutropenia, septic shock and she died. Discussion: These cases highlight that pediatric oncologists and hematologists should be aware of possibility of severe neurological toxicity after administration of ifosfamide in adolescent patients. Apart from seizure, clinicians should also be prepared to notice drowsiness during ifosfamide infusions in children. Most of the time cessation of ifosfamide and hydration is enough. However, in severe toxicities there is a risk of irreversible neurological damage, and for these patients methylene blue (MB) and thiamine treatment should be kept in mind.

6 June 2022 in Child's Nervous System
Verified
Journal Article
Closed access
PDF file
EAEda Ataseven
Eda Ataseven
MÖMuhittin Özcan
Muhittin Özcan
CÖCemile Büşra Ölçülü
Cemile Büşra Ölçülü
EBElif Bolat
Elif Bolat
YEYeşim Ertan
Yeşim Ertan
MKMehmet Kantar
Mehmet Kantar

8 March 2022 in The Journal of Pediatric Research
Verified
Journal Article
Open access
EAEda Ataseven
Eda Ataseven
BKBuket Kosova
Buket Kosova
CACagdas AKTAN
Cagdas AKTAN
ZKZafer Kurugol
Zafer Kurugol
MKMehmet Kantar
Mehmet Kantar

1 January 2020 in Turkish Journal of Ophthalmology
Verified
Journal Article
Open access
NÇNazan Çetingül
Nazan Çetingül
MPMelis Palamar
Melis Palamar
ŞHŞükriye Hacıkara
Şükriye Hacıkara
SKSerra Kamer
Serra Kamer
HÖHamiyet Hekimci Özdemir
Hamiyet Hekimci Özdemir
MHMine Hekimgil
Mine Hekimgil
A 10-year-old girl was brought to the clinic with the complaint of a salmon-colored conjunctival lesion for 1 month. With the aid of histopathological evaluation and other tests, extranodal ocular adnexal marginal zone lymphoma was diagnosed. The patient was graded as T1bN0M0 according to AJCC and Stage 1 according to Ann Arbor classification. She was treated with external radiotherapy at 1.8 Gy/day for 17 days for a total dose of 36 Gy. She is in remission for 26 months and still being followed up.

25 February 2023 in The Turkish Journal of Pediatrics
Verified
Journal Article
Closed access
EAEda Ataseven
Eda Ataseven
ZBZeynep Burak
Zeynep Burak
DSDündar Sabah
Dündar Sabah
BDBaşak Doğanavşargil
Başak Doğanavşargil
MAMehmet Argın
Mehmet Argın
MKMehmet Kantar
Mehmet Kantar
Background. Osteosarcoma is the most common type of primary malignant bone tumor in the extremities. The main purpose of this study was to determine clinical features, prognostic factors, and treatment results of patients with osteosarcoma at our center.Methods. We retrospectively analyzed the medical records of children with osteosarcoma between the years 1994-2020.Results. 79 patients were identified (54.4% male, 45.6% female). The most common primary site was the femur (62%). Twenty-six of them (32.9%) had lung metastasis at diagnosis. The patients were treated between 1995-2013 according to the Mayo Pilot II Study protocol, while the others were treated with the EURAMOS protocol between the years 2013-2020. Sixty-nine patients underwent limb salvage surgery as a local treatment, whereas seven underwent amputation. The median follow-up time was 53 months (2.5-265 months). The event-free survival (EFS) and overall survival (OS) rates at 5 years were 52.1% and 61.5%. The 5-year EFS and OS rates were 69.4% and 80% in females; 37.1% and 45.5% in males (p=0.008/p=0.001). The 5-year EFS and OS rates of the patients without metastasis were 63.2% and 66.3%; with metastasis 28.8% and 51.8% (p=0.002/p=0.05). For good-responders, the 5-year EFS and OS rates were 80.2% and 89.1%; while for poor-responders, 35% and 46.7% (p=0.001). Mifamurtide was used in addition to chemotherapy as of the year 2016 (n=16). The 5-year EFS and OS rates were 78.8% and 91.7%, respectively for the mifamurtide group; 55.1% and 45.9%, respectively for the non-mifamurtide group (p=0.015, p=0.027).Conclusions. Metastasis at diagnosis and poor response to preoperative chemotherapy were the most important predictors of survival. Females had a better outcome than males. In our study group, the mifamurtide group's survival rates were significantly higher. Further large studies are needed to validate the efficacy of mifamurtide.

20 May 2020 in Pediatric Surgery International
Verified
Journal Article
Closed access
PDF file
UCUlgen Celtik
Ulgen Celtik
ZDZafer Dokumcu
Zafer Dokumcu
EDEmre Divarci
Emre Divarci
EGEzgi Guler
Ezgi Guler
EAEda Ataseven
Eda Ataseven
OEOrkan Ergün
Orkan Ergün